Otonomy Provides Corporate and Product Pipeline Update

Back to Jobs

Non-GAAP operating expenses of $85 -$90 million expected in 2017 SAN DIEGO , Jan. 09, 2017 (GLOBE NEWSWIRE) — Otonomy , Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear, today provided

Apply Now